Roche Stock Steady as Oncology and Immunology Drive Earnings Momentum
Roche Holding, one of the largest global healthcare groups, reported steady stock performance driven by its oncology and immunology business.
The company's Pharmaceuticals division accounted for the majority of total revenue in the latest fiscal year, with sales running into tens of billions of Swiss francs. Roche has noted that while some long-established monoclonal antibodies have declined due to biosimilar competition, new launches in oncology and immunology have contributed incremental growth.
The company's diagnostics division also remains a significant contributor to group sales, with revenue in the multi-billion Swiss franc range. Roche expects low-to-mid single-digit percentage growth in sales at constant exchange rates for the current fiscal year, signaling an intention to maintain modest expansion in revenue despite competitive challenges.